Skip to main content
    N

    Novavax Inc (NVAX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $8.06
    -0.46 (-5.45%)

    Market Cap: $1.41B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Novavax Inc (NVAX) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Novavax (NVAX) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Novavax reported EPS of -$0.19, above the -$0.37 estimate. It beat the EPS estimate in 7 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    50%(20/40)
    Avg Surprise
    -2.65%
    Streak
    7 Q

    Upcoming Estimates

    Reports Feb 24, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.55
    Range$0.18 - $0.98
    10 analysts
    Revenue Consensus
    $222.64M
    Range$140.24M - $331.70M
    10 analysts
    Reports May 4, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.35
    Range-$0.45 - -$0.24
    3 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.31-14.0%
    60d ago-$0.31-14.0%
    30d ago-$0.31-14.0%
    7d ago-$0.32-10.4%
    Current-$0.35
    Revenue Consensus
    $35.82M
    Range$28.45M - $43.20M
    2 analysts

    Next Report

    NVAX has an expected report date of Feb 24, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 400.0% above the $0.11 reported for the quarter ended Dec 31, 2025.

    NVAX Earnings Call

    The latest NVAX earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, NVAX beat 20, missed 19 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $68.30M, down 3.0% from $70.44M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.19-$0.37-$0.49 - -$0.23+48.65%BeatN/A71 up, 2 downNov 5, 2026$68.30M
    Jun 30, 2026-$0.32-$0.36-$0.50 - -$0.25+11.11%Beat-151.6%80 up, 4 downAug 6, 2026$56.70M
    Mar 31, 2026-$0.06-$0.37-$0.39 - -$0.06+83.78%Beat-102.0%71 up, 0 downMay 6, 2026$139.51M
    Dec 31, 2025$0.11-$0.66-$1.36 - -$0.11+116.67%BeatN/A70 up, 0 downFeb 26, 2026$147.14M
    Sep 30, 2025-$0.47-$1.13-$1.51 - -$0.19+58.41%BeatN/A70 up, 2 downNov 6, 2025$70.44M
    Jun 30, 2025$0.62$0.06-$0.64 - $0.39+933.33%Beat-37.4%51 up, 1 downAug 6, 2025$239.24M
    Mar 31, 2025$2.93$0.71-$0.58 - $2.67+312.68%BeatN/A51 up, 0 downMay 8, 2025$666.65M
    Dec 31, 2024-$0.52-$0.51-$1.12 - $0.46-1.21%MissN/A50 up, 3 downFeb 27, 2025$88.31M
    Sep 30, 2024-$0.76-$0.75-$1.09 - -$0.46-1.33%MissN/A40 up, 0 downNov 12, 2024$84.51M
    Jun 30, 2024$0.99$1.70$0.41 - $2.56-41.76%Miss+70.7%41 up, 1 downAug 8, 2024$415.48M
    Mar 31, 2024-$1.05-$1.06-$1.48 - -$0.85+0.94%BeatN/A50 up, 0 downMay 10, 2024$93.86M
    Dec 31, 2023-$1.44-$0.35-$1.29 - $0.08-311.43%MissN/A61 up, 0 downFeb 28, 2024$291.34M
    Sep 30, 2023-$1.26-$2.21-$2.79 - $0.28+42.99%BeatN/A60 up, 1 downNov 9, 2023$186.99M
    Jun 30, 2023$0.58-$1.16-$2.50 - -$0.40+150.00%BeatN/A61 up, 0 downAug 8, 2023$424.43M
    Mar 31, 2023-$3.41-$3.46-$3.86 - -$3.05+1.45%Beat-233.2%50 up, 1 downMay 9, 2023$80.95M
    Dec 31, 2022-$2.28-$1.05-$1.44 - -$0.42-117.14%MissN/A41 up, 0 downFeb 28, 2023$357.40M
    Sep 30, 2022-$2.15$1.59-$0.81 - $3.76-235.22%MissN/A61 up, 1 downNov 8, 2022$734.58M
    Jun 30, 2022-$6.53$5.18$4.62 - $7.09-226.06%MissN/A60 up, 1 downAug 8, 2022$185.93M
    Mar 31, 2022$2.56$2.65$1.30 - $3.86-3.40%MissN/A60 up, 0 downMay 9, 2022$703.97M
    Dec 31, 2021-$11.18-$1.80-$5.16 - $7.89-521.11%MissN/A50 up, 2 downFeb 28, 2022$222.20M
    Sep 30, 2021-$4.31-$3.55-$5.04 - -$2.47-21.41%MissN/A61 up, 0 downNov 4, 2021$178.84M
    Jun 30, 2021-$4.75-$3.25-$6.51 - -$1.29-46.15%MissN/A5N/AAug 5, 2021$298.02M
    Mar 31, 2021-$3.05-$3.60-$7.39 - -$1.02+15.28%BeatN/A5N/AMay 10, 2021$447.23M
    Dec 31, 2020-$2.70-$1.49-$2.16 - -$0.68-81.21%MissN/A6N/AMar 1, 2021$318.57M
    Sep 30, 2020-$3.21$1.73-$1.02 - $8.22-285.55%MissN/A5N/ANov 9, 2020$157.02M
    Jun 30, 2020-$0.30-$0.33-$0.94 - $0.48+9.09%BeatN/A5N/AAug 10, 2020N/A
    Mar 31, 2020-$0.58-$0.67-$1.19 - -$0.61+13.43%BeatN/A7N/AMay 11, 2020N/A
    Dec 31, 2019-$1.13-$1.06-$1.39 - -$0.60-6.60%MissN/A7N/AMar 11, 2020$8.82M
    Sep 30, 2019-$1.11-$0.89-$1.23 - -$0.69-24.72%MissN/A6N/ANov 7, 2019$2.51M
    Jun 30, 2019-$1.69-$1.59-$1.86 - -$1.38-6.29%MissN/A7N/AAug 7, 2019$3.36M
    Mar 31, 2019-$2.20-$2.26-$2.60 - -$1.60+2.65%BeatN/A8N/AMay 2, 2019$3.98M
    Dec 31, 2018-$2.60-$2.60-$2.60 - -$1.800.00%In lineN/A9N/AMar 18, 2019N/A
    Sep 30, 2018-$2.40-$2.52-$3.00 - -$1.80+4.76%BeatN/A6N/ANov 7, 2018$7.74M
    Jun 30, 2018-$2.40-$2.46-$2.80 - -$2.20+2.44%BeatN/A8N/AAug 8, 2018$10.77M
    Mar 31, 2018-$2.80-$2.78-$3.00 - -$2.20-0.72%MissN/A7N/AMay 9, 2018$9.65M
    Dec 31, 2017-$3.20-$3.09-$3.60 - -$2.80-3.56%MissN/A8N/AMar 14, 2018$10.41M
    Sep 30, 2017-$3.00-$3.19-$3.40 - -$3.00+5.96%BeatN/A7N/ANov 7, 2017$8.35M
    Jun 30, 2017-$3.20-$3.17-$3.40 - -$3.00-0.95%MissN/A7N/AAug 8, 2017$6.73M
    Mar 31, 2017-$3.20-$3.47N/A+7.78%BeatN/AN/AN/AMay 8, 2017$5.68M
    Dec 31, 2016-$4.20-$4.58N/A+8.30%BeatN/AN/AN/AFeb 27, 2017$5.40M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $3.19, a profit after a loss of $1.34 per share the year before. It was -$20.60 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$3.19N/A
    Dec 31, 2024-$1.34N/A
    Dec 31, 2023-$5.53N/A
    Dec 31, 2022-$8.40N/A
    Dec 31, 2021-$23.29N/A
    Dec 31, 2020-$6.79N/A
    Dec 31, 2019-$6.13N/A
    Dec 31, 2018-$10.20N/A
    Dec 31, 2017-$12.60N/A
    Dec 31, 2016-$20.60N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,200 words across 14 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20269,15414
    2026Q2Jun 30, 20267,82814
    2026Q1Mar 31, 20269,88412
    2025Q4Dec 31, 20252,3849
    2025Q3Sep 30, 20258,36013
    2025Q2Jun 30, 20257,80512
    2025Q1Mar 31, 20257,11012
    2024Q4Dec 31, 20248,23013

    2026Q3 Earnings Call

    Opening remarks

    Naina Zaman Investor Relations Good morning, and thank you for joining us today to discuss our third quarter financial results and operational highlights on November 5, 2026. A press release announcing our results is available on our website at www.novavax.com, and an audio archive of this conference call will be available on our website later today. Before we begin with our prepared remarks, I would like to remind you that this presentation includes forward-looking statements regarding Novavax's current expectations related to, but not limited to, its partnerships, market opportunities, and financial guidance. Our actual results may be materially different from such statements, as detailed in the presentation. Discussions of non-GAAP figures and reconciliations to GAAP figures are available in our earnings press release and presentation. Descriptions of the risks and uncertainties associated with Novavax are included in our SEC filings. These can be accessed through our website. Joining me today are John Jacobs, our President and CEO; Elaine O'Hara, Chief Strategy Officer; Dr. Bob Walker, Head of R&D; and Jim Kelly, our Chief Financial Officer. I would now like to hand the call over to John.

    John Jacobs President and CEO Thank you, Naina, and welcome, everyone. As we near the end of 2026, I'm pleased with the progress we have made this year across the three pillars of our strategy: partnering our vaccine technology, driving targeted and capital-efficient R&D innovation, and maintaining a lean and agile operating model. For those new to our story, Novavax is a vaccine technology company focused on creating long-term value through partnerships. We believe our technology can underpin a broad range of vaccines in infectious disease, from viral to bacterial, and we are in the early stages of exploring its potential in oncology. By combining our own innovation with that of our partners and leveraging their manufacturing scale and commercial reach, we aim to expand access to our technology, unlock new opportunities, and build a legacy of lasting impact on global health. Our technology platform is the engine behind our business, built on a proven foundation in infectious disease. Today, it is used in two commercial vaccines, Nuvaxovid for COVID-19 and R21/Matrix-M for malaria. Both have demonstrated protection against serious disease and favorable tolerability at population scale, with R21/Matrix-M extending that impact to children as young as five months old in malaria-endemic regions. Our technology is also being applied in some of the most attractive vaccine markets. Sanofi recently initiated its phase III influenza COVID-19 combination vaccine trial in Europe. Sanofi management confirmed to us that they are targeting a U.S. phase III start in 2027 to support U.S. approval. The trial in Europe utilizes Novavax's differentiated COVID-19 vaccine and Sanofi's market-leading Fluzone High-Dose influenza vaccine.

    Frequently Asked Questions About NVAX

    When is Novavax's next earnings date?

    Novavax's next earnings report is expected for Feb 24, 2027.

    Did NVAX beat earnings estimates last quarter?

    Yes. Novavax reported EPS of -$0.19 for the quarter ended Sep 30, 2026, above the -$0.37 estimate, a 48.65% surprise.

    What EPS do analysts expect from NVAX next quarter?

    The consensus EPS estimate for Novavax for the quarter ending Dec 31, 2026 is $0.55 from 10 analysts, with estimates from $0.18 to $0.98.

    How often does NVAX beat earnings estimates?

    Novavax beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +195.43%.